For decades, preclinical research has operated under a "male-default" paradigm. Researchers often excluded female subjects to minimize experimental noise caused by estrous cycles or to avoid the confounding neuroprotective effects of estrogen. However, a growing body of evidence suggests that this exclusion creates a significant knowledge gap, as biological sex fundamentally alters disease progression, immune responses, and therapeutic efficacy.
The current research direction focuses on integrating Sex as a Biological Variable (SABV) to move beyond generic models and toward a more precise understanding of how sexual dimorphism shapes pathology.
The Estrogen Shield and Hormonal Modulation
One of the most consistent findings across these papers is the protective role of sex hormones, particularly estrogen, in cardiovascular and metabolic health. When researchers like Wei Xie investigate how nuciferine reduces vascular leakage after a heart attack, they highlight that excluding females ignores the natural vascular stabilization provided by estrogen.
This isn't just about presence or absence; it's about how drugs interact with these hormonal backgrounds. For instance, Wenxiu He found that semaglutide improves cardiac mitophagy to treat heart thickening. However, because estrogen itself influences cardiac remodeling and signaling, findings in male-only cohorts may not accurately predict how a female heart—already under different regulatory pressures—will respond to the same GLP-1 receptor agonist.
Divergent Neural Circuitry and Pain Processing
In neuroscience, the assumption that male and female brains are "functionally identical" is being dismantled. Research into comorbid pain and depression by Yawei Ji shows that ventral pallidal cholinergic circuits drive these behaviors in males. Yet, because biological sex significantly influences immune-to-brain signaling and hormonal cycles, these specific neural "blueprints" may not hold true for females.
This dimorphism extends to molecular signaling. Xiaolin Zhong demonstrated that in female mice, ERK1/2 activation in the anterior cingulate cortex regulates pain-related anxiety but not the physical sensation of pain itself. If researchers only studied males, they might miss these nuanced splits between emotional and sensory processing, leading to analgesics that fail to address the full spectrum of the female patient experience.
Sex-Specific Metabolic and Microbiota Interactions
The "gut-to-brain" axis also appears to be sex-sensitive. When Teng Teng identified that microbiota-driven amino acid deficiencies contribute to pediatric depression, the underlying mechanism involved glutamatergic synapses in the prefrontal cortex. However, metabolic pathways are heavily regulated by sex hormones. Relying on a single sex to model these interactions risks overlooking how hormonal variations—such as those occurring during puberty—influence the way the microbiome communicates with the brain.
Similarly, in aging research, Judith Wackerlig found that hypothalamic lipid profiles distinguish cognitive health in aged rats. Because the hypothalamus is a central hub for hormonal regulation, these lipid "signatures" of aging are likely to look very different in females, who undergo distinct endocrine shifts like menopause.
Toward Representative Modeling
The push for better models is leading to more sophisticated platforms. Jiangping Song and colleagues recently developed a PKP2 knockout pig model for Arrhythmogenic Cardiomyopathy. While a technical milestone, the researchers explicitly noted that failing to account for sex hormones in such large-animal models limits our understanding of disease progression.
The intuition behind this research direction is simple: Biology is not a monolith. By treating sex as a fundamental variable rather than a nuisance to be controlled, researchers can identify why certain treatments work for some but not others, ultimately leading to therapies that are effective for the entire human population.